These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34085768)

  • 1. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients.
    Willmann S; Marostica E; Snelder N; Solms A; Jensen M; Lobmeyer M; Lensing AWA; Bethune C; Morgan E; Yu RZ; Wang Y; Jung SW; Geary R; Bhanot S
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):890-901. PubMed ID: 34085768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI
    Walsh M; Bethune C; Smyth A; Tyrwhitt J; Jung SW; Yu RZ; Wang Y; Geary RS; Weitz J; Bhanot S;
    Kidney Int Rep; 2022 Feb; 7(2):200-209. PubMed ID: 35155859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.
    Ades M; Simard C; Vanassche T; Verhamme P; Eikelboom J; Mavrakanas TA
    Semin Nephrol; 2023 Nov; 43(6):151484. PubMed ID: 38272779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.
    Crosby JR; Marzec U; Revenko AS; Zhao C; Gao D; Matafonov A; Gailani D; MacLeod AR; Tucker EI; Gruber A; Hanson SR; Monia BP
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1670-8. PubMed ID: 23559626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor XI antisense oligonucleotide for prevention of venous thrombosis.
    Büller HR; Bethune C; Bhanot S; Gailani D; Monia BP; Raskob GE; Segers A; Verhamme P; Weitz JI;
    N Engl J Med; 2015 Jan; 372(3):232-40. PubMed ID: 25482425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.
    Younis HS; Crosby J; Huh JI; Lee HS; Rime S; Monia B; Henry SP
    Blood; 2012 Mar; 119(10):2401-8. PubMed ID: 22246038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.
    Winkelmayer WC; Lensing AWA; Thadhani RI; Mahaffey KW; Walsh M; Pap ÁF; Willmann S; Thelen K; Hodge S; Solms A; Ingham SJM; Eikelboom J;
    Kidney Int; 2024 Jul; 106(1):145-153. PubMed ID: 38537676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation factor XI as a novel target for antithrombotic treatment.
    Löwenberg EC; Meijers JC; Monia BP; Levi M
    J Thromb Haemost; 2010 Nov; 8(11):2349-57. PubMed ID: 20727068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and pharmacodynamics of IONIS-GCGR
    Luu KT; Morgan ES; Bhanot S; Geary R; Smith A; Bethune C; Watts L; Henry S; Wang Y
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):179-191. PubMed ID: 28132162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
    Zhang H; Löwenberg EC; Crosby JR; MacLeod AR; Zhao C; Gao D; Black C; Revenko AS; Meijers JC; Stroes ES; Levi M; Monia BP
    Blood; 2010 Nov; 116(22):4684-92. PubMed ID: 20807891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
    Liu T; Hashizume K; Krieg E; Chen H; Mukaida Y; Thelen K; Friedrichs F; Willmann S; Schwers S; Solms A; Yu R
    Clin Transl Sci; 2024 Apr; 17(4):e13784. PubMed ID: 38563414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis.
    Pai SM; Kambhampati SRP; Naruhashi S; Yamada H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):683-690. PubMed ID: 37203396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension.
    Kossmann S; Lagrange J; Jäckel S; Jurk K; Ehlken M; Schönfelder T; Weihert Y; Knorr M; Brandt M; Xia N; Li H; Daiber A; Oelze M; Reinhardt C; Lackner K; Gruber A; Monia B; Karbach SH; Walter U; Ruggeri ZM; Renné T; Ruf W; Münzel T; Wenzel P
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of peritoneal dialysis after abdominal surgery in a patient with factor XI deficiency: A case report.
    Li X; Chen M; Wang Y; Zhou X; Wang M; Zou L
    Semin Dial; 2023 Mar; 36(2):178-182. PubMed ID: 36597266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.
    Edwards AY; Elgart A; Farrell C; Barnett-Griness O; Rabinovich-Guilatt L; Spiegelstein O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1932-1943. PubMed ID: 28294391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
    Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.
    Lorentz CU; Tucker EI; Verbout NG; Shatzel JJ; Olson SR; Markway BD; Wallisch M; Ralle M; Hinds MT; McCarty OJT; Gailani D; Weitz JI; Gruber A
    Blood; 2021 Dec; 138(22):2173-2184. PubMed ID: 34086880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic modeling for hepatic delivery and efficacy of antisense oligonucleotides with lipophilic ligands in mice.
    Watanabe A; Katsube T
    Biopharm Drug Dispos; 2021 Apr; 42(4):178-187. PubMed ID: 33724506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.